Jonathan Lim, Co-Lead of The Manchester Immuno-Oncology Network (MION) and Lead of The Christie International Fellowship Program for Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn:
“Emerging concepts at ESMOImmuno25!
Could in vivo CAR-T therapy become the next big leap in cancer immunotherapy? Its potential to offer true scalability, reduce manufacturing complexity, and overcome many of the logistical challenges of personalised autologous cell therapy makes it an exciting area to watch.
Several excellent talks here in London this year are diving into this rapidly evolving space – looking forward to the discussions and the science that will shape the next generation of cell therapies.”
More posts featuring ESMOImmuno25.